Claim Missing Document
Check
Articles

Found 2 Documents
Search

Platelet-Rich Plasma as a Pharmacopuncture Agent in Cervical Myofascial Pain Nareswari, Irma; Kamal, Achmad Fauzi; Mihardja, Hasan; Yunus, Reyhan Eddy; Jusuf, Ahmad Aulia; Harahap, Alida Roswita; Wahyuni, Luh Karunia; Werdhani, Retno Asti; Handayani, Selfi; Rukmindar, Dion
Proceedings Book of International Conference and Exhibition on The Indonesian Medical Education Research Institute Vol. 9 No. - (2025): Proceedings Book of International Conference and Exhibition on The Indonesian M
Publisher : Writing Center IMERI FMUI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69951/proceedingsbookoficeonimeri.v9i-.310

Abstract

Chronic cervical myofascial pain (CMP) is a prevalent musculoskeletal disorder characterized by persistent neck pain, inflammation, functional impairment, and altered pain processing. Conventional treatments, including pharmacological therapy and physical rehabilitation, often provide limited and temporary relief. Increasing evidence suggests that chronic CMP involves not only peripheral nociceptive input but also nociplastic pain mechanisms driven by sustained neuroimmune dysregulation and central sensitization. Pharmacopuncture, combining acupuncture point stimulation with localized injection of therapeutic agents, has evolved with the introduction of regenerative biologics such as platelet-rich plasma (PRP). PRP contains concentrated platelets and bioactive growth factors, including VEGF, PDGF, and TGF-β, which exert anti-inflammatory and tissue-reparative effects. Emerging data indicate that PRP pharmacopuncture may reduce pro-inflammatory cytokines (e.g., IL-1β and TNF-α), modulate regulated cell death pathways (e.g., apoptosis and pyroptosis), and promote the restoration of myofascial tissue homeostasis. These mechanisms may contribute to both peripheral tissue repair and attenuation of nociplastic pain processing. This narrative review synthesizes current clinical and experimental evidence on the biological mechanisms and therapeutic potential of PRP pharmacopuncture in chronic CMP. Available studies report meaningful improvements in pain intensity and functional outcomes compared with conventional acupuncture or pharmacotherapy alone. However, substantial methodological heterogeneity may arise from PRP preparation protocols, acupoint selection, and outcome measures, limiting the ability to draw definitive conclusions. High-quality randomized controlled trials incorporating standardized protocols and mechanistic biomarkers are required to establish PRP pharmacopuncture as an evidence-based integrative treatment for chronic CMP.
Hyperbaric Oxygen Therapy for Traumatic Brain Injury: A Review Of History, Development, Current Techniques, and Future Directions Wiwoho, Yudi Yuwono; Sadikin, Abdul Halim; Jusuf, Ahmad Aulia; Mulyawan, Wawan; Mudjihartini, Ninik; Ibrahim, Nurhadi; Jusman, Sri Widia A.; Sadikin, Mohamad
Proceedings Book of International Conference and Exhibition on The Indonesian Medical Education Research Institute Vol. 9 No. - (2025): Proceedings Book of International Conference and Exhibition on The Indonesian M
Publisher : Writing Center IMERI FMUI

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69951/proceedingsbookoficeonimeri.v9i-.321

Abstract

Hyperbaric oxygen therapy (HBOT) has gained increasing attention as a potential adjunctive treatment for traumatic brain injury (TBI) patients. This narrative review discusses the historical background, current preclinical and clinical studies, and explores its underlying mechanisms from biomolecular, histological, and clinical perspectives. HBOT promotes neural recovery by improving oxygenation, preserving mitochondrial integrity, enhancing neurotrophic support and synaptic connectivity, mitigating secondary injury pathways (including oxidative stress, inflammation, and apoptosis), and promoting angiogenesis and vascular stability. These mechanisms have demonstrated improvements of motor, cognitive, and memory functions both in preclinical and clinical studies, although outcomes and treatment protocols vary. However, challenges remain regarding optimal protocols, patient selection, and adverse effects. Further high-quality clinical trials are required to define the optimal HBOT regimen are required.